Company intelligence / Profile preview

Biogen

Cambridge, Massachusetts, United Statesbiogen.com ↗

Ownership: Public · BIIB
Employees: ~9000
Development stage: Other

Overview

Biogen has a strong track record in neuroscience drug development with several commercialized therapies for MS and SMA. Its Alzheimer’s drug Aduhelm received FDA approval but has faced controversy over efficacy. The company continues to advance a broad pipeline targeting major neurological diseases.

Therapeutic areas: DermatologyImmunologyPsychiatryNeurology
Modalities: Small moleculesmonoclonal antibodies (mAbs)antisense oligonucleotidesbiosimilars
Industry: Pharma

Drug pipeline

117 assets

interferon beta-1a

Approved

116 more assets in the full pipeline.

Partnerships

Collaborations with Ionis Pharmaceuticals on antisense technologypartnerships with Eisai on Alzheimer’s therapiesother pharma/biotech alliances not detailed here but significant

Financials

Market cap: $36.1B
Total revenue: $9.8B
Enterprise value: $42.6B

Beyond the preview

Go deeper on Biogen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biogen.